A nebulised antitumour necrosis factor receptor-1 domain antibody in patients at risk of postoperative lung injury: A randomised, placebo-controlled pilot study

BACKGROUND: Tumour necrosis factor receptor 1 (TNFR1) signalling mediates the cell death and inflammatory effects of TNF-α. OBJECTIVE: The current clinical trial investigated the effects of a nebulised TNFR1 antagonist (GSK2862277) on signs of lung injury in patients undergoing oesophagectomy. DESIG...

Descripción completa

Detalles Bibliográficos
Autores principales: Ryan, James, Bayliffe, Andrew I., McAuley, Daniel F., Yeung, Joyce, Thickett, David R., Howells, Phillip A., O’Donnell, Ciara, Vassallo, Arlette M., Wright, Tracey J., McKie, Elizabeth, Hardes, Kelly, Summers, Charlotte, Shields, Martin O., Powley, William, Wilson, Robert, Lazaar, Aili L., Fowler, Andrew, Perkins, Gavin D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Ventilation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7575021/
https://www.ncbi.nlm.nih.gov/pubmed/32467417
http://dx.doi.org/10.1097/EJA.0000000000001245

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7575021/
https://www.ncbi.nlm.nih.gov/pubmed/32467417
http://dx.doi.org/10.1097/EJA.0000000000001245

Ejemplares similares